CAI
Caris Life Sciences, Inc.
$15.55
-0.39
(-2.45%)
Mkt Cap
4.40B
Volume
1,804,314
52W Range
14.19-42.5
Sector
Healthcare
Beta
1.09
EPS (TTM)
-1.56
P/E Ratio
-83.86
Revenue (TTM)
907.29M
Rev Growth (5Y)
+22.5%
EPS Growth (5Y)
N/A
Company Description
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 812.03M | 412.26M | 306.13M | 258.49M | 294.01M | 416.54M | 432.10M | 348.39M | 294.35M | 249.67M | 227.59M | 212.41M |
| Net Income | (537.96M) | (281.89M) | (341.42M) | (320.83M) | 27.73M | 31.01M | 78.60M | 72.06M | 6.00M | 26.84M | 60.27M | 63.93M |
| EPS | -1.90 | -2.70 | -1.82 | -1.57 | 1.55 | 1.72 | 3.97 | 3.74 | 0.31 | 1.29 | 2.91 | 2.89 |
| Free Cash Flow | 66.89M | (253.64M) | (298.42M) | (327.96M) | 57.57M | (65.14M) | (633.07M) | (346.98M) | (121.99M) | (242.04M) | N/A | N/A |
| FCF / Share | 0.04 | -1.00 | -1.17 | -1.29 | 3.21 | -3.62 | -31.94 | -18.02 | -6.31 | -11.65 | N/A | N/A |
| Operating CF | 83.16M | (245.20M) | (276.10M) | (285.71M) | 277.02M | 254.00M | 179.77M | 155.19M | 129.26M | 147.37M | N/A | N/A |
| Total Assets | 1.13B | 343.73M | 412.90M | 717.42M | 2.61B | 2.90B | 3.01B | 2.43B | 2.06B | 1.99B | N/A | N/A |
| Total Debt | 378.99M | 424.26M | 217.27M | 270.87M | 1.75B | 2.10B | 2.16B | 1.70B | 1.48B | 1.43B | N/A | N/A |
| Cash & Equiv | 797.80M | 63.95M | 56.40M | 107.19M | 53.55M | 46.46M | 45.31M | 35.42M | 46.13M | 52.55M | N/A | N/A |
| Book Value | 577.31M | (2.50B) | (2.14B) | (1.70B) | 702.24M | 693.24M | 701.13M | 563.85M | 457.50M | 460.34M | N/A | N/A |
| Return on Equity | -0.93 | N/A | N/A | N/A | 0.04 | 0.04 | 0.11 | 0.13 | 0.01 | 0.06 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q2 2024 | Q1 2024 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 216.17M | 292.89M | 216.83M | 181.40M | 120.92M | 100.05M | 80.68M | 100.83M | 85.69M | 80.80M | 64.32M | 79.05M |
| Net Income | (510,000) | 81.96M | 24.32M | (71.79M) | (102.58M) | (66.19M) | (111.03M) | 51.16M | 37.94M | 35.74M | 14.25M | 15.44M |
| EPS | -0.00 | 0.29 | 0.09 | -1.93 | -0.40 | -0.35 | -0.53 | 2.95 | 2.20 | 2.07 | 0.80 | 0.88 |
| Free Cash Flow | 22.53M | 39.69M | 55.33M | 5.90M | (34.03M) | (65.51M) | (75.66M) | (447.56M) | (18.80M) | (95.86M) | (91.42M) | 56.28M |
| FCF / Share | 0.08 | 0.02 | 0.20 | 0.02 | -0.13 | -0.26 | -0.30 | -25.82 | -1.09 | -5.55 | -5.16 | 3.20 |
| Operating CF | 32.88M | 44.78M | 62.42M | 7.29M | (31.34M) | (62.93M) | (73.92M) | 97.61M | 86.28M | 75.79M | 78.81M | 72.58M |
| Total Assets | 1.16B | 1.13B | 984.57M | 955.06M | 291.58M | N/A | N/A | 3.27B | 2.96B | 2.68B | 2.61B | 3.07B |
| Total Debt | 173,000 | 378.99M | 426.74M | 418.98M | 419.83M | N/A | N/A | 2.26B | 1.82B | 1.83B | 1.75B | 2.21B |
| Cash & Equiv | 821.15M | 797.80M | 753.22M | 718.93M | 31.20M | N/A | N/A | 47.03M | 38.81M | 47.91M | 53.55M | 42.30M |
| Book Value | 593.49M | 577.31M | 478.36M | 452.90M | (2.60B) | N/A | N/A | 800.72M | 756.26M | 726.21M | 702.24M | 699.03M |
| Return on Equity | -0.00 | 0.14 | 0.05 | -0.16 | N/A | N/A | N/A | 0.06 | 0.05 | 0.05 | 0.02 | 0.02 |
CAI News
CAI Advances Multicloud and Secure AI Strategy with AWS and Microsoft
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization
Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript
Caris Life Sciences Reports First Quarter 2026 Financial Results
Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis